Aug.17, 2018--The number of cases of progressive massive fibrosis (PMF) among U.S. coal miners has risen during the past two decades, even as the number of coal miners has declined, according to new research published online in the Annals of the American Thoracic Society.
In "Progressive Massive Fibrosis Resurgence Identified in U.S. Coal Miners Filing for Black Lung Benefits, 1970-2016," Kirsten S. Almberg, PhD, and co-authors analyzed data collected by U.S. Department of Labor from 1970 to 2016 under the Federal Black Lung Program. During that time, 4,679 coal miners were diagnosed with PMF, the most debilitating and deadly form of black lung disease ever reported.
"Several other data sources had indicated that PMF, which is caused by over-exposure to coal dust, was on the rise among active coal miners, but no one had characterized the burden of this disease among former miners nationally," said Dr. Almberg, research assistant professor at the University of Illinois at Chicago.
The researchers identified 2,474 cases of PMF in the 21 years between 1996-2016, surpassing the number of cases -2,205--identified in the first 26 years of the program.
Overall, the study found that 84 percent of all PMF cases from 1970 to 2016 occurred in miners who worked in the central Appalachian states of West Virginia (28.4 percent), Kentucky (20.2 percent), Pennsylvania (20 percent) and Virginia (15.3 percent). The miners diagnosed ranged in age from 27 to 93 and averaged 61 years of age.
According to the authors, coal miners working in Virginia experienced the biggest increase in PMF diagnoses--with an average increase of 31.5 percent annually over the study period. The number of miners from Kentucky, West Virginia and Tennessee diagnosed with PMF also grew.
The authors noted that these increases occurred despite the fact that the number of coal miners in the U.S. has declined by more than two-thirds since 1979.
The authors said the study findings were counter intuitive for another reason. The start of the Federal Black Lung Program in 1970 coincided with the adoption of modern dust control measures in mines. Because cumulative dust exposure is an important risk factor for the development of PMF, over time the number of PMF diagnoses should decline.
The authors offered several possible explanations for the increase, including the possibility that miners were exposed to higher dust concentrations than reported and that changes in mining have altered the size, shape and mineralogical composition of coal mine dust in ways that promote fibrosis.
The authors said that, if properly enforced, new Mine Safety and Health Administration coal dust regulations that went into effect in 2014 should help reduce dust exposure in U.S. coal mines.
"Coal mine operators and coal miners should continually be educated about the harmful effects of coal mine dust exposure and become active participants in the dust control programs in their mines," Dr. Almberg said. "The advent of continuous personal dust monitors may provide an opportunity for miners to participate in real-time monitoring and reduce excessive exposures proactively."
She added that increasing the participation rate of working miners in the national surveillance program is "paramount in catching the disease before it progresses to PMF."
Share via Twitter
"Study finds more coal miners are developing #PMF, progressive massive #fibrosis, the worst form of black #lung disease, despite dust regulations in mines and declining number of #coal #miners."
About the Annals of the American Thoracic Society (AnnalsATS)
The AnnalsATS is a peer-reviewed journal published by the American Thoracic Society. The Journal delivers up-to-date and authoritative coverage of adult and pediatric pulmonary and respiratory sleep medicine and adult critical care. The scope of the Journal encompasses content that is applicable to clinical practice, the formative and continuing education of clinical specialists and the advancement of public health. Editor: David Lederer, MD, MS, associate professor of medicine and epidemiology and associate division chief for clinical and translational research at Columbia University.
About the American Thoracic Society
Founded in 1905, the American Thoracic Society is the world's leading medical association dedicated to advancing pulmonary, critical care and sleep medicine. The Society's 15,000 members prevent and fight respiratory disease around the globe through research, education, patient care and advocacy. The ATS publishes three journals, the American Journal of Respiratory and Critical Care Medicine, the American Journal of Respiratory Cell and Molecular Biology and the Annals of the American Thoracic Society.
The ATS will hold its 2019 International Conference, May 17-22, in Dallas, Texas, where world-renowned experts will share the latest scientific research and clinical advances in pulmonary, critical care and sleep medicine.